STOCK TITAN

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) announced its inclusion in the Russell 2000® and 3000® Indices, effective June 28, 2021. This milestone follows a major turnaround in 2020 and the launch of an ambitious Phase 1b/2 program for its CD47-targeting therapies. The Russell indexes are significant benchmarks, with around $10.6 trillion in assets indexed, providing Trillium increased visibility among institutional investors. The company's lead programs include TTI-622 and TTI-621, aimed at enhancing cancer treatment by targeting immune evasion mechanisms.

Positive
  • Inclusion in Russell 2000® and 3000® Indices enhances visibility among institutional investors.
  • Significant market capitalization ranking indicating strong market position.
  • Advancement of Phase 1b/2 clinical programs for TTI-622 and TTI-621 targeting CD47.
Negative
  • None.

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell 2000® and 3000® Indices effective after the US market opens on June 28.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“Trillium’s inclusion in the Russell 2000® index marks an important milestone in the Company’s evolution. After a major turnaround in 2020 and an ambitious Phase 1b/2 program announced in April 2021, Trillium is well positioned as a leader in the CD47 space,” said Jan Skvarka, President and CEO. “We look forward to sharing our story with a broader base of institutional investors over the coming months.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

For more information visit: www.trilliumtherapeutics.com 

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Caution Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable United States federal securities laws and forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, express or implied statements regarding the therapeutic potential of our programs, our clinical development plans and our expectations with respect to the timing of clinical development milestones, including with respect to initiating Phase 1b/2 studies in hematological and solid tumor malignancies and the expected timing of the release of further data on Trillium’s TTI-622 and TTI-621 studies. With respect to the forward-looking statements contained in this press release, Trillium has made numerous assumptions regarding, among other things: the impact of the COVID-19 pandemic on its operations, the effectiveness and timeliness of preclinical and clinical trials; and the completeness, accuracy and usefulness of the data. While Trillium considers these assumptions to be reasonable, these assumptions are inherently subject to significant scientific, business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors that could cause Trillium's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained in this press release. A discussion of risks and uncertainties facing Trillium appears in Trillium's Annual Report on Form 10-K for the year ended December 31, 2020, with the U.S. Securities Exchange Commission, each as updated by Trillium's continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Trillium disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Company Contact:
Rosemary Harrison
SVP, Corporate Development and Strategy
Trillium Therapeutics Inc.
857-412-7029 x225
investors@trilliumtherapeutics.com
www.trilliumtherapeutics.com  

Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com


FAQ

What is the significance of Trillium's inclusion in the Russell 2000® Index?

Trillium's inclusion increases its visibility to institutional investors and signifies its growing market capitalization.

When does Trillium enter the Russell 2000® and 3000® Indices?

Trillium will be included in the Russell 2000® and 3000® Indices effective June 28, 2021.

What therapies is Trillium developing?

Trillium is developing TTI-622 and TTI-621, therapies targeting the CD47 pathway for cancer treatment.

How much capital is benchmarked against Russell indexes?

Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes.

What is the anticipated impact of Russell index inclusion on TRIL stock?

Inclusion may lead to increased trading volume and investment interest, potentially impacting TRIL stock positively.

TRIL

NASDAQ:TRIL

TRIL Rankings

TRIL Latest News

TRIL Stock Data

105.00M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link